Immediate Impact
39 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024 Standout
Works of Nasim Ali being referenced
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
2017 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Nasim Ali | 324 | 110 | 271 | 10 | 394 | |
| Kimitaka Miyajima | 243 | 50 | 135 | 13 | 381 | |
| Kathleen Polson | 241 | 31 | 227 | 9 | 355 | |
| P. Chalabreysse | 335 | 82 | 142 | 9 | 411 | |
| Charles J. McPeak | 280 | 38 | 193 | 11 | 415 | |
| C. Piovesan | 328 | 98 | 151 | 7 | 368 | |
| J. Verwey | 149 | 29 | 216 | 12 | 405 | |
| Kelsey L. Watson | 261 | 65 | 106 | 10 | 394 | |
| Rohini Hawaldar | 196 | 24 | 220 | 16 | 436 | |
| Jianmin Song | 230 | 67 | 243 | 14 | 349 | |
| Kristelle Lusby | 208 | 68 | 95 | 9 | 337 |
All Works
Login with ORCID to disown or claim papers
Loading papers...